Five-year dormant Ebola virus may have triggered Guinea outbreak

In late January, a 51-year-old nurse in Guinea died after being treated for malaria and typhoid fever. Her funeral became a gathering point for transmission. Within days, family members and others who had attended fell ill. Four of them died. By early February, when doctors tested her husband's blood, they found Ebola. The outbreak was declared in mid-February, and the nurse became what epidemiologists call patient zero.

But here is where the story takes an unexpected turn. Three research teams—one at Guinea's Centre for Research and Training in Infectious Diseases, another at the country's National Hemorrhagic Fever Laboratory, and a third at the Pasteur Institute in Dakar—sequenced genetic material from patients in this new outbreak. What they found was striking: the virus matched almost perfectly with the Makona variant that had ravaged West Africa between 2013 and 2016, killing more than 11,300 people across the region. The new samples didn't look like a fresh spillover from animals. They looked like an echo of an epidemic that had ended five years earlier.

The genetic evidence suggested something that challenged conventional understanding of how Ebola spreads. The virus appeared to have been dormant inside a survivor from the earlier epidemic, then reactivated to spark this new outbreak. Eric Delaporte, a researcher at the University of Montpellier who participated in the work, called this scenario "frightening and new." Michael Wiley, a virologist at the University of Nebraska Medical Center, described the current outbreak as a "continuation" of the previous one. Stephan Günther, a virologist at Germany's Bernhard Nocht Institute for Tropical Medicine, noted that scientists had long assumed Ebola outbreaks began when the virus jumped from animals to humans. But these results made that explanation "incredibly unlikely."

The World Health Organization's Mike Ryan, speaking at a press conference, acknowledged the genetic findings and suggested the outbreak was probably triggered by a latent infection that had persisted in the human population since the last epidemic, not by animal-to-human transmission. Yet he emphasized that more investigation was needed. And indeed, other virologists not involved in the sequencing work urged caution. Daniel Bausch, a virologist at the London School of Hygiene and Tropical Medicine, pointed out that the genetic tree showed the virus had "continued in some way in the area, and probably in a survivor," but that didn't prove it had actually lain dormant in one person for five years. The nurse herself was not known to be a survivor of the earlier epidemic, though she could have been infected years ago with minimal symptoms, or exposed through her work to someone who carried the virus. "Finding out exactly what happened is one of the big questions," Bausch said.

Angela Rasmussen, a virologist at Georgetown University, found the results "very surprising." Ebola viruses are not like herpes viruses, which establish chronic infections. RNA viruses generally don't persist without replicating. Yet it was already known that Ebola could linger in the human body far longer than once believed. In 2016, a resurgence in Guinea had been traced to a man who transmitted the virus through semen more than 500 days after his infection was documented. Now, a similar pattern was emerging in the Democratic Republic of Congo, where a new outbreak appeared to have originated from someone infected in an earlier surge.

These findings reshape how scientists think about Ebola's future. If humans can harbor the virus for years, then survivors themselves—not just wildlife—become potential sources of new epidemics. "This is clearly a new paradigm for how outbreaks begin," Delaporte said. The implications are profound. Survivors face not only the physical aftermath of infection but also stigma and, in some cases, violence from their communities. Many may have had mild symptoms and never knew they were infected. Public health campaigns will need to explain which behaviors carry risk—unprotected sex with survivors, for instance—and which do not, like working alongside them or shaking their hands. Clinical monitoring of survivors becomes crucial. Therapeutic options for those carrying dormant virus need development. Vaccination campaigns, which began in Guinea on February 23, offer some protection, but the real challenge now is understanding a virus that doesn't follow the old rules.